What matters about NVAX is the ability to rapidly produce ANY viral vaccine.
No other company has recombinant nanoparticle technology that allows rapid production of a vaccine. Maybe NVAX never has to mass produce a vaccine candidate to fight an outbreak, but they have the capability and capacity to do. That's invaluable.
Exactly.........NVAX may not have the size / scale geographically, but the VLP manufacturing process is the KEY differentiator......and again, it is a PLATFORM......so critical to understand.....its not just MERS, H7N9.......it is whatever comes down the line, the VLP process creates a NEW approach to rapid vaccine development. These recent cases of MERS / H7N9 demonstrate this clearly......VLP will drive a change in how the FDA evaluates and approves vaccines. Big pharma knows this and will strike soon!